Table 2.
Protection against abscess formation by S. aureus CP8
| Treatment (20 μg) | Challenge | No. rats with abscesses/total | P value* |
|---|---|---|---|
| Protection against heterologous polysaccharide challenge | |||
| Saline | CP8 | 24/27 (89%) | — |
| CP8 | CP8 | 7/19 (37%) | 0.0003 |
| PS A | CP8 | 1/20 (5%) | <0.0001 |
| Saline | PS A | 17/20 (85%) | — |
| CP8 | PS A | 3/20 (15%) | <0.0001 |
| PS A | PS A | 3/20 (15%) | <0.0001 |
| Protection against heterologous S. aureus challenge | |||
| Saline | PS80 | 17/20 (85%) | — |
| CP8 | PS80 | 6/18 (33%) | 0.002 |
| PS A | PS80 | 5/19 (26%) | <0.005 |
| S. pneumoniae type 3 CP | PS80 | 6/8 (75%) | NS† |
| Saline | COL | 12/14 (86%) | — |
| CP8 | COL | 4/15 (27%) | 0.003 |
*
Compared with saline-treated control group.
†
NS, not significant.